Hyun Chul Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hyun Chul Kim has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
- In-Jin Jang
Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Korea
10 shared publications - SeungHwan Lee
Department of Clinical Pharmacology and Therapeutics Seoul National University College of Medicine and Hospital Seoul Republic of Korea
5 shared publications - Jae-Yong Chung
Department of Clinical Pharmacology and Therapeutics Seoul National University College of Medicine and Bundang Hospital Gyeonggi‐do Korea
4 shared publications - Jaeseong Oh
Department of Pharmacology, Jeju National University College of Medicine, Jeju, Republic of Korea
3 shared publications - Kyung-Sang Yu
Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul 03080, Republic of Korea
3 shared publications - Eunsol Yang
Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco , San Francisco, California
2 shared publications
Latest Publications
- Open Access
- 28 October 2026
- Published by Wiley in Clinical and Translational Science
- Vol. 19 (11)
Phase 1 Study of Safety and PK With A Combination of Omeprazole and Trimetazidine for Fatty Acid Oxidation Inhibition in Patients With Advanced Solid Tumors
Fatty acid oxidation (FAO) is a metabolic vulnerability in cancer cells, making pharmacologic FAO inhibition a promising therapeutic strategy. This Phase I, open‐label, 3 + 3 dose‐escalation study evaluated the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of two oral FAO inhibitors—omeprazole (KN510), a carnitine–acylcarnitine translocase inhibitor, and trimetazidine (KN713), an acetyl‐CoA acyltransferase inhibitor—given once daily in combination to patients with advanced solid tumors. Twelve patients were enrolled across four dose cohorts (omeprazole and trimetazidine, each 60–120 mg/day). The maximum tolerated dose was not reached; the recommended Phase 2 dose was set at 120 mg once daily for each agent. Treatment was generally well tolerated, with most adverse events Grade 1–2; the most common were flu‐like symptoms (25.0%), constipation (16.7%), nausea (16.7%), and dizziness (16.7%). Omeprazole showed time‐dependent pharmacokinetics consistent with auto‐inhibition of its own metabolism, whereas trimetazidine showed dose‐proportional pharmacokinetics across the studied range. The best response was stable disease in five patients (disease control rate 41.7%). Median progression‐free survival was 1.66 months (95% CI, 1.18–3.55) and median overall survival was 9.13 months (95% CI, 3.29–not reached). Dual pharmacologic FAO inhibition with oral omeprazole and trimetazidine was feasible and well tolerated, supporting the mechanistic rationale for combination dosing. Disease stabilization observed in this heavily pretreated population warrants further clinical evaluation, particularly in combination with standard chemotherapy regimens. Trial Registration: ClinicalTrials.gov , NCT06012708; registered August 25, 2023
- 28 October 2026
- Published by Wiley in Clinical and Translational Science
- Vol. 19 (11)
Open AccessPhase 1 Study of Safety and PK With A Combination of Omeprazole and Trimetazidine for Fatty Acid Oxidation Inhibition in Patients With Advanced Solid Tumors
Fatty acid oxidation (FAO) is a metabolic vulnerability in cancer cells, making pharmacologic FAO inhibition a promising therapeutic strategy. This Phase I, open‐label, 3 + 3 dose‐escalation study evaluated the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of two oral FAO inhibitors—omeprazole (KN510), a carnitine–acylcarnitine translocase inhibitor, and trimetazidine (KN713), an acetyl‐CoA acyltransferase inhibitor—given once daily in combination to patients with advanced solid tumors. Twelve patients were enrolled across four dose cohorts (omeprazole and trimetazidine, each 60–120 mg/day). The maximum tolerated dose was not reached; the recommended Phase 2 dose was set at 120 mg once daily for each agent. Treatment was generally well tolerated, with most adverse events Grade 1–2; the most common were flu‐like symptoms (25.0%), constipation (16.7%), nausea (16.7%), and dizziness (16.7%). Omeprazole showed time‐dependent pharmacokinetics consistent with auto‐inhibition of its own metabolism, whereas trimetazidine showed dose‐proportional pharmacokinetics across the studied range. The best response was stable disease in five patients (disease control rate 41.7%). Median progression‐free survival was 1.66 months (95% CI, 1.18–3.55) and median overall survival was 9.13 months (95% CI, 3.29–not reached). Dual pharmacologic FAO inhibition with oral omeprazole and trimetazidine was feasible and well tolerated, supporting the mechanistic rationale for combination dosing. Disease stabilization observed in this heavily pretreated population warrants further clinical evaluation, particularly in combination with standard chemotherapy regimens. Trial Registration: ClinicalTrials.gov , NCT06012708; registered August 25, 2023
- Open Access
- 1 March 2026
- Vol. 15 (3) , e70208
Population Pharmacokinetic-Pharmacodynamic Analysis of Zolpidem in Healthy Volunteers: Covariate Contributions to Variability in CNS Responses.
Population pharmacokinetic-pharmacodynamic (PK-PD) modeling was used to explore covariate effects on zolpidem PKs and PDs in 30 healthy Korean volunteers (15 males, 15 females) who received a single 10 mg dose. The dataset included 325 PK observations and 388 observations each for the digit symbol substitution test (DSST), choice reaction time (CRT), and visual analog scale (VAS). A one-compartment PK model with transit compartment absorption and first-order elimination was developed, followed by sequential sigmoid Emax-based direct response models for each PD endpoint. A hyperbolic learning effect model was incorporated for DSST, whereas CRT showed no clear learning effect. Baseline VAS was described using linear splines. No clinically meaningful covariates were retained in the final PK or PK-VAS models. In contrast, higher body weight was associated with reduced DSST IC50 and CRT EC50. Lower albumin was associated with increased potency for both DSST and CRT and with a steeper concentration-response relationship for CRT. Higher baseline CRT values were linked to greater potency and a steeper slope for CRT, and older age was associated with lower baseline DSST and CRT performance. These exploratory findings suggest that variability in zolpidem response may be partially mediated by physiologically and functionally relevant factors, such as body weight, albumin, age, and baseline PD measures, which could complement sex in individualized risk assessment.
- 1 March 2026
- Vol. 15 (3) , e70208
Open AccessPopulation Pharmacokinetic-Pharmacodynamic Analysis of Zolpidem in Healthy Volunteers: Covariate Contributions to Variability in CNS Responses.
Population pharmacokinetic-pharmacodynamic (PK-PD) modeling was used to explore covariate effects on zolpidem PKs and PDs in 30 healthy Korean volunteers (15 males, 15 females) who received a single 10 mg dose. The dataset included 325 PK observations and 388 observations each for the digit symbol substitution test (DSST), choice reaction time (CRT), and visual analog scale (VAS). A one-compartment PK model with transit compartment absorption and first-order elimination was developed, followed by sequential sigmoid Emax-based direct response models for each PD endpoint. A hyperbolic learning effect model was incorporated for DSST, whereas CRT showed no clear learning effect. Baseline VAS was described using linear splines. No clinically meaningful covariates were retained in the final PK or PK-VAS models. In contrast, higher body weight was associated with reduced DSST IC50 and CRT EC50. Lower albumin was associated with increased potency for both DSST and CRT and with a steeper concentration-response relationship for CRT. Higher baseline CRT values were linked to greater potency and a steeper slope for CRT, and older age was associated with lower baseline DSST and CRT performance. These exploratory findings suggest that variability in zolpidem response may be partially mediated by physiologically and functionally relevant factors, such as body weight, albumin, age, and baseline PD measures, which could complement sex in individualized risk assessment.
- Open Access
- 26 February 2026
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 15 (3)
Population Pharmacokinetic–Pharmacodynamic Analysis of Zolpidem in Healthy Volunteers: Covariate Contributions to Variability in CNS Responses
Population pharmacokinetic–pharmacodynamic (PK–PD) modeling was used to explore covariate effects on zolpidem PKs and PDs in 30 healthy Korean volunteers (15 males, 15 females) who received a single 10 mg dose. The dataset included 325 PK observations and 388 observations each for the digit symbol substitution test (DSST), choice reaction time (CRT), and visual analog scale (VAS). A one‐compartment PK model with transit compartment absorption and first‐order elimination was developed, followed by sequential sigmoid E max ‐based direct response models for each PD endpoint. A hyperbolic learning effect model was incorporated for DSST, whereas CRT showed no clear learning effect. Baseline VAS was described using linear splines. No clinically meaningful covariates were retained in the final PK or PK–VAS models. In contrast, higher body weight was associated with reduced DSST IC 50 and CRT EC 50 . Lower albumin was associated with increased potency for both DSST and CRT and with a steeper concentration‐response relationship for CRT. Higher baseline CRT values were linked to greater potency and a steeper slope for CRT, and older age was associated with lower baseline DSST and CRT performance. These exploratory findings suggest that variability in zolpidem response may be partially mediated by physiologically and functionally relevant factors, such as body weight, albumin, age, and baseline PD measures, which could complement sex in individualized risk assessment.
- 26 February 2026
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 15 (3)
Open AccessPopulation Pharmacokinetic–Pharmacodynamic Analysis of Zolpidem in Healthy Volunteers: Covariate Contributions to Variability in CNS Responses
Population pharmacokinetic–pharmacodynamic (PK–PD) modeling was used to explore covariate effects on zolpidem PKs and PDs in 30 healthy Korean volunteers (15 males, 15 females) who received a single 10 mg dose. The dataset included 325 PK observations and 388 observations each for the digit symbol substitution test (DSST), choice reaction time (CRT), and visual analog scale (VAS). A one‐compartment PK model with transit compartment absorption and first‐order elimination was developed, followed by sequential sigmoid E max ‐based direct response models for each PD endpoint. A hyperbolic learning effect model was incorporated for DSST, whereas CRT showed no clear learning effect. Baseline VAS was described using linear splines. No clinically meaningful covariates were retained in the final PK or PK–VAS models. In contrast, higher body weight was associated with reduced DSST IC 50 and CRT EC 50 . Lower albumin was associated with increased potency for both DSST and CRT and with a steeper concentration‐response relationship for CRT. Higher baseline CRT values were linked to greater potency and a steeper slope for CRT, and older age was associated with lower baseline DSST and CRT performance. These exploratory findings suggest that variability in zolpidem response may be partially mediated by physiologically and functionally relevant factors, such as body weight, albumin, age, and baseline PD measures, which could complement sex in individualized risk assessment.
- Open Access
- 1 January 2026
- Published by XMLink in Translational and Clinical Pharmacology
- Vol. 34 (2) , 88-99
Pharmacokinetics and safety of nafamostat and its metabolites following single- and multiple-dose oral administration of nafamostat mesylate in healthy male participants
Hong JK, et al. Transl Clin Pharmacol. 2026 Jun;34(2):88-99. https://doi.org/10.12793/tcp.2026.34.e7
- 1 January 2026
- Published by XMLink in Translational and Clinical Pharmacology
- Vol. 34 (2) , 88-99
Open AccessPharmacokinetics and safety of nafamostat and its metabolites following single- and multiple-dose oral administration of nafamostat mesylate in healthy male participants
Hong JK, et al. Transl Clin Pharmacol. 2026 Jun;34(2):88-99. https://doi.org/10.12793/tcp.2026.34.e7
- Open Access
- 14 October 2025
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 92 (3) , 860-868
Pharmacokinetics, pharmacodynamics and safety of vutiglabridin after multiple oral administrations in healthy female and obese subjects
Aims: Vutiglabridin (HSG4112) is a novel drug under clinical development for antiobesity treatment. This study aimed to evaluate the pharmacokinetics (PKs) and safety of vutiglabridin after multiple oral administrations in healthy Korean female and obese subjects and explore short‐term pharmacodynamic (PD) responses. Methods: Two separate randomized, double‐blind, placebo‐controlled studies were conducted in healthy female and obese subjects. The subjects in each dose group (480 or 720 mg) received vutiglabridin or placebo once daily for 14 days under fed conditions at an 8:2 ratio. Serial blood samples were collected on days 1 and 14 for PK analysis. PD biomarkers related to obesity and inflammation were assessed, and safety and tolerability were evaluated throughout the study. Results: At steady state, obese subjects exhibited a 9%–13% higher maximum concentration (C max,ss ) and a 17%–19% lower area under the plasma concentration–time curve for a dosing interval at steady state (AUC τ,ss ). This profile reflects altered absorption and distribution due to obesity‐related physiological changes. After 14 days of treatment, compared with healthy females, obese subjects had greater decreases in baseline‐corrected body weights in the 480 mg, 720 mg and placebo groups. Vutiglabridin was safe and well tolerated in both groups. Conclusions: Vutiglabridin presented higher peak plasma concentrations but lower systemic exposure in obese subjects than in healthy females. Additionally, a modest downward trend in body weight was observed in obese subjects relative to healthy female subjects. These findings support further long‐term phase II clinical trials.
- 14 October 2025
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 92 (3) , 860-868
Open AccessPharmacokinetics, pharmacodynamics and safety of vutiglabridin after multiple oral administrations in healthy female and obese subjects
Aims: Vutiglabridin (HSG4112) is a novel drug under clinical development for antiobesity treatment. This study aimed to evaluate the pharmacokinetics (PKs) and safety of vutiglabridin after multiple oral administrations in healthy Korean female and obese subjects and explore short‐term pharmacodynamic (PD) responses. Methods: Two separate randomized, double‐blind, placebo‐controlled studies were conducted in healthy female and obese subjects. The subjects in each dose group (480 or 720 mg) received vutiglabridin or placebo once daily for 14 days under fed conditions at an 8:2 ratio. Serial blood samples were collected on days 1 and 14 for PK analysis. PD biomarkers related to obesity and inflammation were assessed, and safety and tolerability were evaluated throughout the study. Results: At steady state, obese subjects exhibited a 9%–13% higher maximum concentration (C max,ss ) and a 17%–19% lower area under the plasma concentration–time curve for a dosing interval at steady state (AUC τ,ss ). This profile reflects altered absorption and distribution due to obesity‐related physiological changes. After 14 days of treatment, compared with healthy females, obese subjects had greater decreases in baseline‐corrected body weights in the 480 mg, 720 mg and placebo groups. Vutiglabridin was safe and well tolerated in both groups. Conclusions: Vutiglabridin presented higher peak plasma concentrations but lower systemic exposure in obese subjects than in healthy females. Additionally, a modest downward trend in body weight was observed in obese subjects relative to healthy female subjects. These findings support further long‐term phase II clinical trials.
- Open Access
- 18 August 2025
- Published by Wiley in Clinical and Translational Science
- Vol. 18 (8) , e70326
First‐In‐Human Study of Safety, Tolerability, Efficacy, and Pharmacokinetics of CPNE7‐Derived Peptide (Selcopintide) for Dentin Hypersensitivity
Dentin hypersensitivity is characterized by transient, sharp pain resulting from dentin exposure due to enamel or cementum loss. Current treatments, which primarily focus on superficial tubule occlusion or nerve desensitization, provide only temporary relief. Copine7 (CPNE7) induces odontoblast differentiation and physiologic dentin regeneration, enabling biological dentin sealing and presenting a novel therapeutic approach. This study reports the first‐in‐human results of a randomized, double‐blind, dose‐escalation phase 1/2a clinical trial evaluating the safety, tolerability, preliminary efficacy, and pharmacokinetics of the CPNE7‐derived functional peptide (selcopintide) in patients with dentin hypersensitivity. In Part A (Single Ascending Dose, SAD), 24 participants received a single topical application of selcopintide at ascending doses (2.5, 5, and 10 μg/tooth) in a 6:2 randomization ratio (treatment: placebo). In Part B (Multiple Ascending Dose, MAD), 16 participants received three topical applications (5 and 10 μg/tooth) over 15 days (day 1, 8, and 15; visits 2–4) with the same randomization ratio. Efficacy endpoints were assessed by changes in cold water, evaporative air, and tactile sensitivity. In Part B, the 10 μg selcopintide group demonstrated statistically significant reductions from the baseline across all three measures (p < 0.05), with a mean decrease of −23.2 ± 19.4 mm in VAS, the primary efficacy endpoint. All doses were well tolerated, with no serious adverse events and no detectable systemic absorption of selcopintide. These findings support the safety, tolerability, and preliminary efficacy of selcopintide as a novel therapeutic candidate for the treatment of dentin hypersensitivity.
- 18 August 2025
- Published by Wiley in Clinical and Translational Science
- Vol. 18 (8) , e70326
Open AccessFirst‐In‐Human Study of Safety, Tolerability, Efficacy, and Pharmacokinetics of CPNE7‐Derived Peptide (Selcopintide) for Dentin Hypersensitivity
Dentin hypersensitivity is characterized by transient, sharp pain resulting from dentin exposure due to enamel or cementum loss. Current treatments, which primarily focus on superficial tubule occlusion or nerve desensitization, provide only temporary relief. Copine7 (CPNE7) induces odontoblast differentiation and physiologic dentin regeneration, enabling biological dentin sealing and presenting a novel therapeutic approach. This study reports the first‐in‐human results of a randomized, double‐blind, dose‐escalation phase 1/2a clinical trial evaluating the safety, tolerability, preliminary efficacy, and pharmacokinetics of the CPNE7‐derived functional peptide (selcopintide) in patients with dentin hypersensitivity. In Part A (Single Ascending Dose, SAD), 24 participants received a single topical application of selcopintide at ascending doses (2.5, 5, and 10 μg/tooth) in a 6:2 randomization ratio (treatment: placebo). In Part B (Multiple Ascending Dose, MAD), 16 participants received three topical applications (5 and 10 μg/tooth) over 15 days (day 1, 8, and 15; visits 2–4) with the same randomization ratio. Efficacy endpoints were assessed by changes in cold water, evaporative air, and tactile sensitivity. In Part B, the 10 μg selcopintide group demonstrated statistically significant reductions from the baseline across all three measures (p < 0.05), with a mean decrease of −23.2 ± 19.4 mm in VAS, the primary efficacy endpoint. All doses were well tolerated, with no serious adverse events and no detectable systemic absorption of selcopintide. These findings support the safety, tolerability, and preliminary efficacy of selcopintide as a novel therapeutic candidate for the treatment of dentin hypersensitivity.
- Open Access
- 1 January 2025
- Published by XMLink in Translational and Clinical Pharmacology
- Vol. 33 (2) , 66-79
Quantitation of methotrexate polyglutamates in red blood cells and application in patients with Crohn’s disease
Kim H, et al. Transl Clin Pharmacol. 2025 Jun;33(2):66-79. https://doi.org/10.12793/tcp.2025.33.e7
- 1 January 2025
- Published by XMLink in Translational and Clinical Pharmacology
- Vol. 33 (2) , 66-79
Open AccessQuantitation of methotrexate polyglutamates in red blood cells and application in patients with Crohn’s disease
Kim H, et al. Transl Clin Pharmacol. 2025 Jun;33(2):66-79. https://doi.org/10.12793/tcp.2025.33.e7
- Open Access
- 1 July 2024
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 18, 2641-2652
Pharmacokinetic Interactions Between the Fixed-Dose Combination of Ezetimibe/Rosuvastatin 10/20 Mg and the Fixed-Dose Combination of Telmisartan/Amlodipine 80/5 Mg in Healthy Subjects
Background: Management of hypertension and hyperlipidemia, which are common comorbid risk factors for cardiovascular diseases, require multiple medications. The development of a fixed-dose combination (FDC) containing ezetimibe, rosuvastatin, telmisartan, and amlodipine aims to enhance patient adherence and persistence, but the potential interactions among the four medications have not been studied. This study aimed to evaluate the pharmacokinetic (PK) interactions between the FDC of ezetimibe/rosuvastatin 10/20 mg (ER) and the FDC of telmisartan/amlodipine 80/5 mg (TA). Methods: An open-label, single-sequence, three-period, three-treatment crossover study was conducted in healthy male subjects. All subjects received ER for 7 days, TA for 9 days and ER combined with TA for 7 days during each treatment period. For PK analysis of total/free ezetimibe, rosuvastatin, telmisartan, and amlodipine, serial blood samples were collected for 24 hours at steady state. Safety profiles were assessed throughout the study. Results: Thirty-eight subjects were enrolled, and 34 subjects completed the study. The systemic exposure to each active ingredient after coadministration of the two FDCs was similar to that after each FDC alone. The geometric mean ratios and 90% confidence intervals for the maximum plasma concentration (mu g/L) and the area under the plasma concentration-time curve (hmu g/L) of the combination therapy to monotherapy, assessed at steady state, were as follows: total ezetimibe, 1.0264 (0.8765-1.2017) and 0.9359 (0.7847-1.1163); free ezetimibe, 1.5713 (1.2821-1.9257) and 0.9941 (0.8384-1.1788); rosuvastatin, 2.1673 (1.7807-2.6379) and 1.1714 (0.9992-1.3733); telmisartan, 1.0745 (0.8139-1.4186) and 1.1057 (0.8379-1.4591); and amlodipine, 0.9421 (0.8764-1.0126) and 0.9603 (0.8862-1.0405). Both combination therapy and monotherapy were well tolerated by the subjects. Conclusion: The coadministration of ezetimibe/rosuvastatin 10/20 mg and ezetimibe/rosuvastatin 10/20 mg was well tolerated in healthy subjects, and the PK interaction between those two FDCs was not clinically significant.
- 1 July 2024
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 18, 2641-2652
Open AccessPharmacokinetic Interactions Between the Fixed-Dose Combination of Ezetimibe/Rosuvastatin 10/20 Mg and the Fixed-Dose Combination of Telmisartan/Amlodipine 80/5 Mg in Healthy Subjects
Background: Management of hypertension and hyperlipidemia, which are common comorbid risk factors for cardiovascular diseases, require multiple medications. The development of a fixed-dose combination (FDC) containing ezetimibe, rosuvastatin, telmisartan, and amlodipine aims to enhance patient adherence and persistence, but the potential interactions among the four medications have not been studied. This study aimed to evaluate the pharmacokinetic (PK) interactions between the FDC of ezetimibe/rosuvastatin 10/20 mg (ER) and the FDC of telmisartan/amlodipine 80/5 mg (TA). Methods: An open-label, single-sequence, three-period, three-treatment crossover study was conducted in healthy male subjects. All subjects received ER for 7 days, TA for 9 days and ER combined with TA for 7 days during each treatment period. For PK analysis of total/free ezetimibe, rosuvastatin, telmisartan, and amlodipine, serial blood samples were collected for 24 hours at steady state. Safety profiles were assessed throughout the study. Results: Thirty-eight subjects were enrolled, and 34 subjects completed the study. The systemic exposure to each active ingredient after coadministration of the two FDCs was similar to that after each FDC alone. The geometric mean ratios and 90% confidence intervals for the maximum plasma concentration (mu g/L) and the area under the plasma concentration-time curve (hmu g/L) of the combination therapy to monotherapy, assessed at steady state, were as follows: total ezetimibe, 1.0264 (0.8765-1.2017) and 0.9359 (0.7847-1.1163); free ezetimibe, 1.5713 (1.2821-1.9257) and 0.9941 (0.8384-1.1788); rosuvastatin, 2.1673 (1.7807-2.6379) and 1.1714 (0.9992-1.3733); telmisartan, 1.0745 (0.8139-1.4186) and 1.1057 (0.8379-1.4591); and amlodipine, 0.9421 (0.8764-1.0126) and 0.9603 (0.8862-1.0405). Both combination therapy and monotherapy were well tolerated by the subjects. Conclusion: The coadministration of ezetimibe/rosuvastatin 10/20 mg and ezetimibe/rosuvastatin 10/20 mg was well tolerated in healthy subjects, and the PK interaction between those two FDCs was not clinically significant.
- Open Access
- 15 December 2023
- Published by Springer Nature in Investigational New Drugs
- Vol. 42 (1) , 80-88
Effects of food and ethnicity on the pharmacokinetics of venadaparib, a next-generation PARP inhibitor, in healthy Korean, Caucasian, and Chinese male subjects
Aim: Venadaparib is a next-generation poly(ADP-ribose) polymerase inhibitor under development for treating gastric cancer. This study aimed to evaluate the effects of food and ethnicity on the pharmacokinetics (PKs) and safety of venadaparib after a single oral administration in healthy Korean, Caucasian, and Chinese male subjects. Methods: In this randomized, open-label, single-dose, two-sequence, two-period, and crossover study, Korean and Caucasian subjects received venadaparib 80 mg in each period (fasted or fed state) with a seven-day washout. In an open-label, single-dose study, Chinese subjects received venadaparib 80 mg only in the fasted state. Serial blood samples were collected up to 72 h post-dosing. Results: Twelve subjects from each ethnic group completed the study. The geometric mean ratios (90% confidence intervals) of the maximum plasma concentration (Cmax) and area under the plasma concentration-time curve from time zero to the last measurable time point (AUClast) of venadaparib for the fed to fasted state were 0.82 (0.7457–0.9094) and 1.02 (0.9088–1.1339) in Koreans, and 0.77 (0.6871–0.8609) and 0.96 (0.9017–1.0186) in Caucasians, respectively. No statistically significant differences were observed in Cmax (P-value = 0.45) or AUClast (P-value = 0.30) among the three ethnic groups. A single venadaparib dose was well-tolerated. Conclusion: The overall systemic exposure of venadaparib was not affected by the high-fat meal, despite delayed absorption with a decreased Cmax in the fed state. The PK profiles were comparable among the Korean, Caucasian, and Chinese subjects. A single venadaparib 80 mg dose was safe and well-tolerated in both fasted and fed states.
- 15 December 2023
- Published by Springer Nature in Investigational New Drugs
- Vol. 42 (1) , 80-88
Open AccessEffects of food and ethnicity on the pharmacokinetics of venadaparib, a next-generation PARP inhibitor, in healthy Korean, Caucasian, and Chinese male subjects
Aim: Venadaparib is a next-generation poly(ADP-ribose) polymerase inhibitor under development for treating gastric cancer. This study aimed to evaluate the effects of food and ethnicity on the pharmacokinetics (PKs) and safety of venadaparib after a single oral administration in healthy Korean, Caucasian, and Chinese male subjects. Methods: In this randomized, open-label, single-dose, two-sequence, two-period, and crossover study, Korean and Caucasian subjects received venadaparib 80 mg in each period (fasted or fed state) with a seven-day washout. In an open-label, single-dose study, Chinese subjects received venadaparib 80 mg only in the fasted state. Serial blood samples were collected up to 72 h post-dosing. Results: Twelve subjects from each ethnic group completed the study. The geometric mean ratios (90% confidence intervals) of the maximum plasma concentration (Cmax) and area under the plasma concentration-time curve from time zero to the last measurable time point (AUClast) of venadaparib for the fed to fasted state were 0.82 (0.7457–0.9094) and 1.02 (0.9088–1.1339) in Koreans, and 0.77 (0.6871–0.8609) and 0.96 (0.9017–1.0186) in Caucasians, respectively. No statistically significant differences were observed in Cmax (P-value = 0.45) or AUClast (P-value = 0.30) among the three ethnic groups. A single venadaparib dose was well-tolerated. Conclusion: The overall systemic exposure of venadaparib was not affected by the high-fat meal, despite delayed absorption with a decreased Cmax in the fed state. The PK profiles were comparable among the Korean, Caucasian, and Chinese subjects. A single venadaparib 80 mg dose was safe and well-tolerated in both fasted and fed states.
- Open Access
- 7 December 2023
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 11 (2) , 424-435
Topiramate dosage optimization for effective antiseizure management via population pharmacokinetic modeling
Objective: Despite the suggested topiramate serum level of 5–20 mg/L, numerous institutions have observed substantial drug response at lower levels. We aim to investigate the correlation between topiramate serum levels, drug responsiveness, and adverse events to establish a more accurate and tailored therapeutic range.Methods: We retrospectively analyzed clinical data collected between January 2017 and January 2022 at Seoul National University Hospital. Drug responses to topiramate were categorized as “insufficient” or “sufficient” by reduction in seizure frequency ≥ 50%. A population pharmacokinetic model estimated serum levels from spot measurements. ROC curve analysis determined the optimal cutoff values.Results: A total of 389 epilepsy patients were reviewed having a mean dose of 178.4 ± 117.9 mg/day and the serum level, 3.9 ± 2.8 mg/L. Only 5.6% samples exhibited insufficient response, with a mean serum level of 3.6 ± 2.5 mg/L while 94.4% demonstrated sufficient response, with a mean 4.0 ± 2.8 mg/L, having no statistical significance. Among the 69 reported adverse events, logistic regression analysis identified a significant association between ataxia and serum concentration (p = 0.04), with an optimal cutoff value of 6.5 mg/L.Interpretation: This study proposed an optimal therapeutic concentration for topiramate based on patients' responsiveness to the drug and the incidence of adverse effects. We recommended serum levels below 6.5 mg/L to mitigate the risk of ataxia‐related side effects while dose elevation was found unnecessary for suboptimal responders, as the drug's effectiveness plateaus at minimal doses.
- 7 December 2023
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 11 (2) , 424-435
Open AccessTopiramate dosage optimization for effective antiseizure management via population pharmacokinetic modeling
Objective: Despite the suggested topiramate serum level of 5–20 mg/L, numerous institutions have observed substantial drug response at lower levels. We aim to investigate the correlation between topiramate serum levels, drug responsiveness, and adverse events to establish a more accurate and tailored therapeutic range.Methods: We retrospectively analyzed clinical data collected between January 2017 and January 2022 at Seoul National University Hospital. Drug responses to topiramate were categorized as “insufficient” or “sufficient” by reduction in seizure frequency ≥ 50%. A population pharmacokinetic model estimated serum levels from spot measurements. ROC curve analysis determined the optimal cutoff values.Results: A total of 389 epilepsy patients were reviewed having a mean dose of 178.4 ± 117.9 mg/day and the serum level, 3.9 ± 2.8 mg/L. Only 5.6% samples exhibited insufficient response, with a mean serum level of 3.6 ± 2.5 mg/L while 94.4% demonstrated sufficient response, with a mean 4.0 ± 2.8 mg/L, having no statistical significance. Among the 69 reported adverse events, logistic regression analysis identified a significant association between ataxia and serum concentration (p = 0.04), with an optimal cutoff value of 6.5 mg/L.Interpretation: This study proposed an optimal therapeutic concentration for topiramate based on patients' responsiveness to the drug and the incidence of adverse effects. We recommended serum levels below 6.5 mg/L to mitigate the risk of ataxia‐related side effects while dose elevation was found unnecessary for suboptimal responders, as the drug's effectiveness plateaus at minimal doses.